Nilotinib is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). The product is expected to be launched in FY 2025-26 in the United States. Additionally, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback